Mesoblast, a leader in cell-based therapies, announced that its product Ryoncil® received coverage from the Centers for Medicare and Medicaid Services (CMS).
This agreement ensures access to this newly FDA-approved mesenchymal stromal cell therapy for children with steroid-refractory acute graft versus host disease (SR-aGvHD) covered by Medicaid.
Consequently, the first three pediatric patients will begin receiving Ryoncil® treatment this week for this life-threatening condition.
Ryoncil® is the first such cell therapy approved in the U.S., offering a crucial treatment option for a vulnerable patient population. Mesoblast is also actively developing other cell therapies for various inflammatory conditions.
Listen to our latest podcast episode below for full details:
For more info visit: https://www.ryoncil.com/
